Evidence map›Paper›PMID 18587383›Full record

ReviewNature reviews. Drug discovery2008

Creating and evaluating genetic tests predictive of drug response.

Scott T Weiss, Howard L McLeod, David A Flockhart, M Eileen Dolan, Neal L Benowitz, Julie A Johnson, Mark J Ratain, Kathleen M Giacomini

Abstract readReview
In one paragraph

Review in Nature reviews. Drug discovery, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. An iterative searching and ranking algorithm for prioritising pharmacogenomics genes.International journal of computational biology and drug design · 2013
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Is the use of sentient animals in basic research justifiable?Philosophy, ethics, and humanities in medicine : PEHM · 2010
    Review
  15. Article
  16. Improving the prediction of pharmacogenes using text-derived drug-gene relationships.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2010
    Article
  17. Article
  18. Population-based discovery of toxicogenomics biomarkers for hepatotoxicity using a laboratory strain diversity panel.Toxicological sciences : an official journal of the Society of Toxicology · 2009
    Article
  19. Are animal models predictive for humans?Philosophy, ethics, and humanities in medicine : PEHM · 2009
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Scott T WeissChanning Laboratory, Brigham and Women's Hospital, 181 Longwood Ave, Boston, Massachusetts 02115, USA. scott.weiss@channing.harvard.edu
Howard L McLeod
David A Flockhart
M Eileen Dolan
Neal L Benowitz
Julie A Johnson
Mark J Ratain
Kathleen M Giacomini

Funding

Whole GenomeU01GM061393 · NIGMS · UNIVERSITY OF CHICAGO · PI COX, NANCY J, DOLAN, MARY EILEEN · 2000 to 2014
$39.0M
THE PHARMACOGENETICS OF ASTHMA TREATMENTU01HL065899 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI TANTISIRA, KELAN G, WEISS, SCOTT T · 2000 to 2014
$38.5M
PHARMACOGENETICS OF MEMBRANE TRANSPORTERSU01GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GIACOMINI, KATHLEEN M · 2000 to 2009
$29.2M
University of Toronto Coordinating Genetics Core & Clinical Trial SiteU01DA020830 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI SWAN, GARY E · 2005 to 2014
$22.4M
Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI COOPER-DEHOFF, RHONDA M, JOHNSON, JULIE A. · 2005 to 2014
$20.7M
POPULATION GENETICS AND DRUG METABOLISMU01GM063340 · NIGMS · WASHINGTON UNIVERSITY · PI MCLEOD, HOWARD L · 2001 to 2009
$17.4M
TAMAXIFEN PHARMACOGENETICSU01GM061373 · NIGMS · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI FLOCKHART, DAVID ALASTAIR · 2000 to 2009
$17.0M
Pharmacogenomics of Membrane TransportersU19GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SALI, ANDREJ · 2010 to 2014
$16.3M
NHLBI NIH HHS U01 HL065899NIDA NIH HHS DA 20830NIDA NIH HHS U01 DA020830NIGMS NIH HHS GM61390NIGMS NIH HHS GM61393NIGMS NIH HHS U01 GM061373NIGMS NIH HHS U01 GM061390NIGMS NIH HHS U01 GM061393NIGMS NIH HHS U01 GM063340NIGMS NIH HHS U01 GM074492NIGMS NIH HHS U01 GM63340NIGMS NIH HHS U19 GM061390
6 · The paper itself

Abstract

A key goal of pharmacogenetics--the use of genetic variation to elucidate inter-individual variation in drug treatment response--is to aid the development of predictive genetic tests that could maximize drug efficacy and minimize drug toxicity. The completion of the Human Genome Project and the associated HapMap Project, together with advances in technologies for investigating genetic variation, have greatly advanced the potential to develop such tests; however, many challenges remain. With the aim of helping to address some of these challenges, this article discusses the steps that are involved in the development of predictive tests for drug treatment response based on genetic variation, and factors that influence the development and performance of these tests.

Indexed as

Genetic TestingPharmacogeneticsDrug TherapyForecastingGenetic VariationHumans

Identifiers

PMID18587383
PMCPMC2682785

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.